Allograft Dysfunction in Heart Transplant

Conditions

• Heart Transplant Failure and Rejection

Eligibility Criteria

Sex

ALL

Age

18 Years - N/A

Healthy Volunteers

Not accepted

Interventions

• Regadenoson — DRUG
  For use in stress myocardial perfusion imaging.

Study Details

The investigators will evaluate for early evidence of cardiac allograft dysfunction by cardiac MRI and single cell sequencing to determine underlying molecular and macroscopic causes.

Key Dates

Start date

Oct 1, 2019

Status verified

Apr 2026

Primary completion

Jan 1, 2027

Completion

Jan 2, 2027

Study Design

Enrollment

376 participants (estimated)

Allocation

NON_RANDOMIZED

Intervention model

PARALLEL

Primary purpose

DIAGNOSTIC

Arms

• Experimental: Nonspecific allograft dysfunction
  Patients with nonspecific allograft dysfunction will undergo stress cardiac MRI with regadenoson in addition to performing late gadolinium enhancement and obtaining mean segmental T1 values of the heart. Peripheral blood and endomycardial biopsies will also be obtained for single cell RNAseq analyses.
• Experimental: Normal graft function
  Patients with normal graft function will undergo stress cardiac MRI with regadenoson in addition to performing late gadolinium enhancement and obtaining mean segmental T1 values of the heart. Peripheral blood and endomycardial biopsies will also be obtained for single cell RNAseq analyses.
• Experimental: Cardiac allograft vasculopathy
  Patients with allograft dysfunction from known cardiac allograft dysfunction will undergo stress cardiac MRI with regadenoson in addition to performing late gadolinium enhancement and obtaining mean segmental T1 values of the heart. Peripheral blood and endomycardial biopsies will also be obtained for single cell RNAseq analyses.
• Experimental: ACR/AMR
  Patients with allograft dysfunction from prior episodes of acute cellular or antibody mediated rejection will undergo stress cardiac MRI with regadenoson in addition to performing late gadolinium enhancement and obtaining mean segmental T1 values of the heart. Peripheral blood and endomycardial biopsies will also be obtained for single cell RNAseq analyses.

Primary Outcome Measure

Myocardial Perfusion Reserve [ Time Frame: 60 months ]

Central Contacts

• Paul Kim, MD
  8582460638
  [email protected]

Locations (1)

Find similar trials in La Jolla, CA

Related Studies

• Valganciclovir vs. Letermovir for CMV Prophylaxis in Heart Transplant
  PHASE2/PHASE3 · Recruiting · Columbia University · New York, New York